• 18 Sep 2017 8:59 AM | Anonymous

    Author: Bert McClary, RPh

    At the August meeting, the group discussed the practice advancement legislation proposal, agenda topics from the June 23 and July 12 BOP meetings and pharmacy/drug-related sections of SB 501 that become effective August 28.

    Practice Advancement Legislation Group

    • A multidisciplinary practice advancement group was convened in January and has met three times.  The MSHP Public Policy and Practice Advancement Initiative Committees are leaders in this effort.  The meetings are open and between 15 and 20 persons have participated in each meeting.  While most are MSHP members, there is regular attendance by MPA, BOP, UMKC and StLCOP.  LTC pharmacists have participated and an additional effort is being be made to have chain stores and nuclear pharmacies represented.
    • At the August 25 meeting in Columbia, proposed pharmacy practice act language was agreed on that includes authority to prescribe drugs including controlled substances, removal of the requirement for a prescription to implement a medication therapy services protocol, and removal of the term medication therapeutic plan.  Language is also proposed to be changed in the controlled substances act to allow prescribing of controlled substances by pharmacists, which will provide the basis for a pharmacist DEA registration.
    • Although MPA members and staff have participated in the group, the MPA board of directors has not yet voted to support or promote the legislation.  MPA retains a lobbyist and has a formal process for sponsoring legislation which their board requires to be followed, but they do wish to work together with the other organizations in this effort.  MSHP members have strongly recommended that support and sponsorship also be solicited from the Missouri Hospital Association, and MHA staff have expressed interest.  A meeting with MHA staff, who have considerable experience in promoting legislation, is being arranged.  All participants have emphasized that this must be a true collaborative effort that is supported by all pharmacy practice settings.
    • The MSHP PAI members are continuing to refine a Q&A, and will develop examples of advanced practices that will show the patient care benefits of increased pharmacist participation in direct patient care.
    • A chairperson had not been previously designated, and Daniel Good accepted a request to serve in this position.  Daniel is past-president of MSHP, serves on the MPA board of directors, is a member of the BOP Hospital Advisory Committee, has worked directly with MHA on pharmacy-related projects and will be able to coordinate this multidisciplinary group.
    • A core “executive group” will meet on September 21 to make decisions on next steps to move the effort forward.

    The Public Policy Committee meets by telephone conference the first Thursday of each month at 4:00 p.m.  The new chair is Amy Benson, Director of Pharmacy at Liberty Hospital.  If you would like to join the conversations and if there are public policy/regulatory issues that you would like to discuss, contact Amy at abenson@libertyhospital.org.
  • 18 Sep 2017 8:49 AM | Anonymous

    Author: Bert McClary, RPh

    The HAC met in Jefferson City on August 7

    • Class J Shared Services Rule.  An emergency amendment became effective August 7 that will allow a licensed pharmacy to deliver a filled and labeled prescription to another licensed pharmacy without being licensed under Class J if the medication is to be administered on the same premises as the receiving pharmacy.  This amendment was based on current problems caused when specialty pharmacies could not deliver medications to a pharmacy/clinic for administration to the patient at the clinic because it was not possible obtain a Class J permit between the two pharmacies. 
    • The Board is working with DHSS, the Department of Mental Health and others to implement provisions of new legislation related to opioid abuse and misuse, including a standing order for naloxone, MoHealthNet billing, patient education, insurance and distribution of free supplies from DMH.
    • New legislation allows hospitals to be licensed if they are in compliance with CMS Conditions of Participation, and places restrictions on DHSS hospital licensing rules.  The definition of licensed premises is unclear under the new requirements and is significant to BOP licensing regarding certain practice sites.  DHSS and MHA are working together to interpret the law and DHSS will make proposals for rule changes.  HAC will review the previously proposed changes to the DHSS pharmacy services and medication management rule and make a recommendation to DHSS regarding sections that should be implemented.
    • Suggestions were made regarding proposed pharmacy practice advancement legislation, to be forwarded to the task force that is preparing the language.
    • Proposed technician legislation was reviewed and concerns were expressed regarding the effect of sterile compounding being placed in the advanced technician category.  The potential for DHSS and BOP to propose a joint rule regarding technician activities was discussed, to be considered if the proposed legislation is not successful or if the final language is not satisfactory.
    • Greg Teale was elected to serve as Chairman.
    • Strategic review of committee operations was deferred to the next meeting, to include a more complete review of previous activities, membership, scope of authority and future topics.

  • 18 Sep 2017 8:37 AM | Anonymous

    Author: Bert McClary, RPh

    The Board met on July 12 in open session with several MSHP members present and participating. 

    • Governor-mandated public rule comment period.  Members of the public commented on rules including pharmacist CE for drug administration and maintenance of electronic prescription records.
    • Draft legislation proposal for technicians.  There is concern that the governor’s office wants restriction of oversight by state agencies rather than expansion.  Topics discussed during the meeting for further changes in the proposal included age requirements, advanced technician roles, nuclear technician CE, registration of trainees, and oversight by pharmacist during training.  A final version was to be reviewed by the Board and presented to the Governor’s office in early August, but this version has not been publicly distributed.
    • Other proposed legislation.  Additional proposals agreed to move forward included clarifying the role of third-party logistics providers and changing pharmacist CE to a biennial period rather than annual.
    • Required rule review.  Although hospital pharmacist interest is usually focused on inpatient-related issues, more hospital pharmacists are showing interest in Board rules for outpatient pharmacy as well.  Board members were again reminded of the Governor’s request for a reduction in the number of mentions of “shall” and “must.”  Lengthy discussions were held regarding five rules scheduled under the previous Governor’s required Rule Review 2020, and seven draft rule proposals that are in process, including:
      • Compounding Standards of Practice.  Updating is needed, including consideration of USP 795.  Postpone for one year due to other priorities.
      • Nuclear.  A nuclear subcommittee will recommend minimum changes and wait for USP 825 requirements.
      • Standards of Operation.  Miscellaneous editorial and minor changes recommended.
      • Supervision.  A new rule proposal would address current supervision requirements and new concepts such as remote technician supervision.  Recommended to focus first on final verification of a prescription/order, considering technology and credentials and qualifications of technicians.  Later discussion of types and definitions of remote supervision.  Hospital pharmacists expressed concerns about expansion of remote hospital physician clinics with no pharmacy services onsite that could be addressed with remote supervision.
      • Administration by prescription order.  Removal of CE requirement.
      • Vaccines by protocol.  Change CE requirements to 2 hours per 2 years.
    • A Governor’s Task Force on Boards and Commissions is still meeting with Boards and discussing possible changes such as combining various boards, inspector qualifications (e.g.: non-pharmacist inspectors), salaries, CE for staff, and technology.  Board staff emphasized the need for continuity and expertise of pharmacist inspectors and retaining separation from other medical professional boards.  Board member appointments are still anticipated this summer.
    • Proposed Patient Safety Conference and Opioid Conference are still on hold.
    • A webinar is scheduled to review new 2017 legislation, most of which will become effective August 28.  Legislation will also be reviewed in the August BOP Newsletter.
    • Board Officers.  Christian Tadrus was elected President.  Christian is a past-president of MPA and a principal in the Missouri Pharmacist Care Network supporting advanced clinical practice in community pharmacy.  Although Christian does not support expanded technician roles, he has been a friend of hospital pharmacy and has represented community pharmacy in various Board hospital pharmacy issues for a number of years, including the Hospital Advisory Committee.  Doug Lang, a perennial hospital pharmacy promoter, is serving a new term on the Board after being absent for several years and was elected Vice President.

  • 25 Jul 2017 2:56 PM | Deleted user

    By John Neill, PharmD Candidate 2018, and Courtney Kominek, PharmD, BCPS, CPE

    Gabapentin and pregabalin are widely     prescribed in chronic pain. Food and Drug Administration (FDA)-approved indications for gabapentin and pregabalin include post-herpetic neuralgia and epilepsy.1,2 In addition, pregabalin is FDA-approved for neuropathic pain (diabetic or spinal cord injury) and fibromyalgia.2 These gabapentinoids are frequently prescribed off-label for various reasons including post-operative pain, hot sweats, generalized anxiety disorder, and substance use disorders.3,4 Per the Controlled Substance Act, pregabalin is a Schedule V drug indicating it has the least likelihood for abuse among the 5 classes of controlled substances. Pregabalin was classified as a controlled substance based on the data from clinical trials. These trials showed that pregabalin causes positive psychic effects similar to alprazolam and diazepam, as well as acute euphoric effects seen at a higher proportion than expected.5 Gabapentin is not a controlled substance.3 Up until recently, gabapentin and pregabalin have been regarded as having low levels of abuse and being safe. This thought is rapidly changing and the reasoning behind this change will be described in this article.

    Many drugs of abuse including alcohol, benzodiazepines, and non-benzodiazepine hypnotics display effects on gamma-aminobutyric acid (GABA) receptors.3 Gabapentinoids have structures that are similar to GABA, but they do not directly interact with GABA receptors or impact GABA uptake or production.6 It has been proposed that gabapentin may interfere with GABA metabolism, as well as cause the release of GABA allowing it to interact with its receptors.4 Gabapentinoids also reduce neurotransmitter release and the influx of calcium by binding to the alpha-2-delta subunit of voltage-gated calcium channels potentially causing their anticonvulsant, anxiolytic, and antinociceptive effects. It is believed, that not only do gabapentinoids cause euphoric effects most commonly attributed to GABA moderating drugs, but they may also cause dissociative effects through their interaction with the dopaminergic system.3 This dopaminergic relationship may also be the cause for the addictive potential of these drugs with the reward system being activated through this interaction. These dopaminergic effects are not typically seen with the other GABA modifying medications.3,4 In addition to the above effects associated with gabapentinoid abuse, other unexpected effects have been reported by abusers. These effects include relaxation and a high described as being similar to a high from marijuana, ‘zombie-like’ effects, and enhanced sociability.4

    Gabapentinoid abuse is most common among the younger population, generally occurring in the 30s, on average. Risk factors for abusing gabapentinoids include a history of cocaine use, combination marijuana and benzodiazepine use at high rates, psychiatric patients, prisoners, and opioid abusers. The data for abuse rates for males vs. females is conflicting, with some studies showing higher rates in males, while others show higher rates in females. The prevalence of gabapentinoid abuse is much higher in this patient population and this problem has been on the rise in recent years. U.S. opioid abusers misused gabapentin and pregabalin as much as clonazepam and 2 times more than amphetamines. Gabapentinoid abuse is of particular concern in patients who currently abuse opioids or have a history of opioid abuse. Studies that have been done that have specifically assessed people with opioid use disorders and gabapentinoid abuse show pregabalin being abused at rates ranging from 3-68%, and gabapentin being abused at rates ranging from 15-22%. When comparing this to a study that showed the general population in the United Kingdom abusing pregabalin and gabapentin at rates of 1.1 and 0.5%, it shows you the alarming difference in rates of abuse between opioid use disorder patients and the general population.3Gabapentin dosing for post-herpetic neuralgia starts with 300 mg on day 1, 300 mg twice daily on day 2, and 300 mg three times daily on day 3, titrating up as needed to a max of 1800 mg/day; however, gabapentin may be dosed up to 3600 mg/day in divided doses for other conditions. Pregabalin dosing is recommended to start at 150 mg/day for all indications. This is typically divided into 2 to 3 doses per day. The general titration schedule is to increase to the max dose per indication based on tolerability and efficacy within 1 week. Max doses for pregabalin vary from 300 mg/day to 600 mg/day based on indication.2 Both medications require dosage adjustments for reduced renal function when creatinine clearance is below 60 mL/min.1,2.

    Per individual case reports for gabapentinoid abusers, pregabalin abuse ranged anywhere between 800 to 7,500 mg per dose, with the median dose being 2,100 mg; and gabapentinoid abuse was anywhere between 1,000 and 12,000 mg per dose, with the median dose being 3,600 mg. These are typically single supratherapeutic doses when abused. Tachyphylaxis develops rapidly, so repeat abusers commonly increase the dose as they continue to abuse. U.S. poison centers have reported doses ranging up to 96,000 mg of gabapentin and 9,000 mg of pregabalin. No deaths occurred due to these high doses and outcomes were mostly mild to moderate. These reports indicate an advantageous adverse effect profile for these drugs; however, they are being seen on toxicology reports on an increasing basis. When pregabalin and gabapentin are used in conjunction with other central nervous system depressants, overdose deaths are more frequent.3

    Typical abuse occurs via oral route, but intravenous routes, rectal plugging, smoking, and parachuting have been reported. Often times gabapentinoids are abused in conjunction with other drugs like alcohol, benzodiazepines, marijuana, opioids, lysergic acid diethylamide (LSD), selective-serotonin reuptake inhibitors, and quetiapine.3,4 People who abuse gabapentinoids typically acquire them with a legal prescription, from their family members or friends, or may purchase them online. Gabapentin on the black market ranges from $1 to $7 per pill.3

    A concern related to gabapentinoid abuse is physical dependence and withdrawal symptoms. Withdrawal symptoms can be caused by sudden discontinuation of gabapentin or pregabalin. Withdrawal with gabapentinoids are very similar to what is seen with alcohol and benzodiazepine withdrawal, likely due to their effects on GABA.3 Symptoms that can result from alcohol and benzodiazepine withdrawal include anxiety, tremors, sweating, irritability, cognitive dysfunction, psychosis, and seizures, which can be life-threatening.7 Treatment for benzodiazepine and alcohol withdrawal involves using primarily benzodiazepines to help relieve symptoms. Benzodiazepine treatment for gabapentinoid withdrawal is ineffective, but fast relief can be attained by the administration of gabapentinoids. Re-administering gabapentinoids and slowly tapering the dose is the ideal way to treat gabapentinoid withdrawal.3

    Some states have taken their own action to address this issue. The State Board of Pharmacy in Ohio made a rule effective on December, 1st 2016 requiring pharmacies, wholesalers, and prescribers to submit the specified dispensing, personal furnishing, or wholesale sale information on gabapentin to the Ohio Automated Rx Reporting System.8 In addition to the changes to gabapentin in Ohio, a rule went into effect in Kentucky on July 1, 2017 making gabapentin a Schedule V controlled substance resulting in the requirement of the administering and dispensing of gabapentin to be reported to Kentucky All Schedule Prescription Electronic Reporting (KASPER).9 It is highly likely that as time goes on more states will continue to adopt similar rules to help reduce the misuse and abuse of gabapentin.

    Pharmacists are in a critical position to help reduce the spread of the abuse and misuse of pregabalin and gabapentin. Pharmacists can help raise awareness to this problem and make sure these medications are being used for legitimate purposes and that the doses are appropriate and do not exceed the maximum recommended dosages. It is important that pharmacists are aware of the warning signs of abuse such as frequent early refill request, patients requesting to pay out of pocket when they have insurance, multiple prescriptions for the same medication from different doctors, frequent transfers for that medication, and patients wanting their prescription early because it was ‘stolen or misplaced.’ We also need to pay particular attention to patients taking gabapentinoids who have substance abuse disorders, specifically people using opioids or with psychiatric issues.3


    1.  Neurontin [package insert]. New York, NY: Pfizer; 2015.
    2.  Lyrica [package insert]. New York, NY: Pfizer; 2016.
    3.  Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403.
    4.  Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491-496.
    5.  Leonhart MM. Schedules of controlled substances: placement of pregabalin into Schedule V. DEA diversion website. https://www.deadiversion.usdoj.gov/fed_regs/rules/2005/fr0728.htm. July 2005. Accessed: June 27th, 2017.
    6.  Gabapentin. Lexi-Comp OnlineTM, Hudson, Ohio: Lexi-Comp, Inc.; Accessed: June 27th, 2017.
    7.  Freynhagen R, Backonja M, Schug S, et al. Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs. 2016;30:1191.
    8.  Reporting gabapentin to OARRS. State of Ohio Board of Pharmacy website. http://pharmacy.ohio.gov/Documents/Pubs/Special/OARRS/Reporting Gabapentin Products to OARRS – Effective 12-1-2016.pdf. July 2016. Accessed: June 28, 2017.
    9.  KASPER (Kentucky All Schedule Prescription Electronic Reporting). Cabinet for Health and Family Services in Kentucky website. http://www.chfs.ky.gov/os/oig/KASPER.htm. June 2017. Accessed: July 6, 2017.
  • 25 Jul 2017 2:47 PM | Deleted user

    Author: Kyle Klindworth, UMKC SSHP Chapter President in Kansas City and Kaitlyn Lee, UMKC SSHP Chapter President in Columbia

    This fall, UMKC SSHP had a membership drive that lasted throughout the first month of school and included many events. During the first week of classes, our school holds a "Lunch on the Lawn" event, which is essentially a student organization fair. At this event, we made a poster for our organization and had members of our executive board stand and give students information about joining the three organizations. We also held an informational SSHP general meeting early in the fall semester, to recruit membership from pharmacy students from all classes. During the 2016-2017 school year, across all three campuses, we recruited 120 members to join SSHP, MSHP, and the local chapters!

    SSHP held the Clinical Skills Competition last October as a two-day event in an effort to increase student participation. The majority of students that partake in the event are typically fourth year students on rotations, so switching to a two-day event made the competition more successful. The first day was the case work-up. The judges reviewed the cases and the top teams were asked to present their cases on day two. This year we had ten teams of two students participate in the contest, and the winning team was sent to compete in the national competition at Mid-Year.

    The UMKC SSHP Chapter also holds an annual “Residency Roundtable” in the Fall semester of the school year to provide students with tips for success related to residencies. This event facilitates the students' understanding of what is required to obtain a residency and what is expected of a resident. This year the event was held on October 1, 2016 with 42 student attendees. We invited current residents across the country to attend as well as their residency directors. Fifteen different residency programs were represented at the event. This provided students with a diverse group of residents and exposure to the many different areas of pharmacy. Diane McClaskey, RPh, BCPS gave a keynote presentation with useful tips for becoming a successful candidate for residency programs as well as helpful tips when interviewing, and the importance of residencies to the field of pharmacy. After the keynote, there was a panel discussion where the programs answered questions that students had regarding residencies followed by a lunch/networking session that lasted roughly 2 hours. Students were able to ask questions about programs and residency in general. After the networking session, there were two additional presentations about how to apply for residency programs and about the ASHP Mid-Year Clinical Meeting. Dr. Stephanie Schauner gave a presentation about PhORCAS and Dr. Barbara Kasper discussed ASHP Mid-Year Clinical Meeting tips. Both Dr. Schauner and Dr. Kasper gave insight into the general application process and interview information.

    UMKC School of Pharmacy has three locations across Missouri, providing a unique opportunity for students to work with MSHP and the local affiliates/pharmacists involved in those communities. The goal of this project was to increase awareness of Health-System Pharmacists during National Pharmacy Week 2016. On the Springfield campus, SSHP members worked with the MSHP Secretary and Past-President to contact local radio and television stations and share public service announcements from ASHP. The PSA announcements were disseminated to four television stations and over 15 radio stations. For the Columbia location, the SSHP President (Columbia) worked with the President of Mid-Missouri SHP and the MSHP Secretary to provide these PSA announcements to local radio stations.

    Last, but not least, UMKC SSHP continues to play a role in improving patient care within the community. One project that we have continued to be involved with is the Vial of Life project to further patient safety and continuity of care. The Vial of Life program allows our SSHP chapter to distribute vials to community members, particularly the elderly, at local health fairs and community events. Our members assist patients in completing an up-to-date home medication list and provide them with a sticker to place in their window so emergency personnel can find the list and obtain information about the patient's medication history. We believe that the Vial of Life project is a great way to help members of our community in a time when they need it most – during an emergency. We see this as a way to improve patient safety and provide continuity of care to patients, even when we are not physically with them. In total, we were able to distribute vials to over 120 patients in the community!

  • 25 Jul 2017 2:45 PM | Deleted user

    Author: Dip Patel, St. Louis College of Pharmacy SSHP Chapter President

    St. Louis College of Pharmacy’s SSHP main focus over the past year was to provide an organization where students can exercise their leadership abilities while learning about Health-System pharmacy. Over the past year, we implemented 11 chair and co-chair positions to increase SSHP’s student involvement, increase the quality and quantity of our events, and encouraged students to take on more active roles. Our events have doubled with over 14 new events, and student leadership and involvement has increased within our organization, thus helping our members prepare for their future careers. STLCOP’s SSHP also had two students holding a national position – Joanna Huang was a member of the PSF Advancement of Pharmacy Practice and Dip Patel was a member of the PSF Leadership Development Advisory Group.

    At the beginning of the year, SSHP promoted and participated in MSHP’s Fall meeting “Share the Vision.” Throughout the meeting, students were given the opportunity to attend many different sessions including topics of career and professional development. This meeting provided students with an opportunity to review their CV’s and meet with MSHP leaders. Our SSHP chapter emulated MSHP’s vision throughout the year to make our own events focusing on career and professional development for our students.

    SSHP provided students with a tour opportunity at Mallinckrodt. The Nuclear Tour at Mallinckrodt provided insight to students as to how nuclear medicines are manufactured and what nuclear clinical pharmacists do on a daily basis. For most students, this was their first exposure to a nuclear medicine facility, and they were able to enhance their understanding of a potential career.

    Our SSHP chapter also held the first-ever Practice Advancement Initiative (PAI) Week at St. Louis College of Pharmacy. It is one of ASHP’s best-known initiatives to promote and advance the profession of pharmacy. Many students on campus are unaware of PAI week, so SSHP’s goal was to educate students on PAI and discuss ways students can maximize our profession’s potential.

    SSHP’s annual Clinical Skills Competition always provides students with a great professional and academic development opportunity through a clinical knowledge competition. We encouraged students to utilize their knowledge and compete for a chance to represent STLCOP at Midyear.

    Throughout the year, we provided a three part series to introduce students to residencies. The first part focused on the underlying basics of residencies. The second part focused on how students can make a great CV that showcases their professional development throughout school. The third part of the series focused on having faculty critique students’ CVs such that they could make necessary improvements. This Residency Series was many students’ first exposure to residencies and provided both undergraduate and professional students information on what career options can be made possible with a residency.

    Additionally, we gave students exposure to non-traditional pharmacy careers by having Poison Control and Home Infusion Lunch and Learns. They were able to interact with pharmacists who worked in these settings to improve their understanding on the daily functions of their positions. This was an educational experience for students that developed their knowledge and understanding on a unique career.

    Towards the end of the year, we held an Aseptic Technique Lab. We provided hands-on lab experience with preparing IV bags. This will help students on hospital rotations and future careers.

    Over the next year, we plan to continue having new seminars, as well as service and networking opportunities to inspire students to explore their passion in health-systems pharmacy.

  • 25 Jul 2017 2:38 PM | Deleted user

    As always, a lot is happening at the UMKC School of Pharmacy! Here are a few highlights to catch you up on recent activities at the school.

    Outstanding Student Pharmacists! Once again, our chapter of the American Pharmacists Association- Academy of Student Pharmacists (APhA-ASP) continued to shine and bring national attention to UMKC! At the 2017 annual meeting of the APhA, our student chapter was recognized as the Division AA first runner up placing them in the top seven APhA-ASP chapters in the nation! Also at the APhA meeting, Elizabeth Rodman was recognized as the recipient of the nationally acclaimed Boyle Family Scholarship from the APhA Foundation, and Sara Massey was selected to serve on the APhA-ASP National Communications Standing Committee. Most recently, we had two participants in the competitive American Association of Colleges of Pharmacy Walmart Scholars Program: Sara Massey and Janna Brown. Many congratulations to all of our students who continue to do so well, and bring recognition to their school!

    Outstanding Faculty! It is no wonder to me why our student pharmacists have been so successful. The answer is simple, they are led by outstanding faculty. In recent faculty news, we are proud that our own Dr. Jeremy Hampton was sworn in as the new President of the Missouri Society of Health Systems Pharmacists. Also in health system pharmacy, Dr. Andy Smith was named the Pharmacist of the Year by the Greater Kansas City Society of Health Systems Pharmacists. Dr. Lisa Cillessen and her colleagues at Jordan Valley Community Health Center received recognition from the American Diabetes Association for their Diabetes Education Program. We have another nationally recognized diabetes educator, and that is Dr. Andrew Bzowyckyj who was featured as a Member Highlight on the American Association of Diabetes Educator website. Also recognized on a nationally was the work that our own Dr. Kelly Cochran who in collaboration with her team from Mizzou and Lincoln University were recognized in the U.S. National Food and Agriculture 2016 Annual Report for their work to minimize health risks and avoid re-injury related to prescription medications for disabled farmers! In basic science research, Dr. Simon Friedman was awarded the 2017 UMKC Trustees Faculty Fellow Award as well as the UMKC NT Veatch Award for Distinguished Research and Creativity. And, Dr. Ashim Mitra was awarded the 2017 Dr. Roger Vogel Award for Pharmaceutical Research from the Association for Research in Vision and Ophthalmology. Congratulations to all of these faculty successes!

    Dr. Beth Winans. The School of Pharmacy greatly misses our dear friend and colleague, Dr. Beth Winans who passed away after a long and courageous battle with cancer in December of 2016. Beth joined UMKC in 2007. Her practice was mostly at Truman Medical Centers’ Behavior Health Department, where she taught student pharmacists and medical teams. She was recognized nationally by the College of Psychiatric and Neurologic Pharmacists with the Innovative Practice Award, signifying her hard work, dedication and creativity in behavioral health.

    Faculty Changes. Bitter sweet is how we describe our feelings for the upcoming retirement of Dr. Peggy Kuehl. Dr. Kuehl served the school for many years as the director of our community pharmacy residence program among many other teaching responsibilities in the school. We will greatly miss her, but we also wish Peggy well in her new adventures after retirement in the fall. The school is eagerly awaiting the start of new faculty joining the school. Dr. Diana Tamer will join us in the fall. Her expertise is oncology and her practice site will be at Shawnee Mission Health. We are grateful to our partners there who helped us recruit Diana and will welcome her into their practice. Also joining us in the fall is Dr. Melissa Palmer who has expertise in psychiatric pharmacotherapy. Her practice site will be at North Kansas City hospital. And, Dr. Sarah Oprinovich was recruited to serve as our new director of the community pharmacy residency program in collaboration with Balls Food Stores. Welcome aboard to Drs. Tamer, Palmer, and Oprinovich.

    Student Changes. As always, the accomplishment that we are most proud of at UMKC is our graduates. May 2017 marked the celebration of 123 Pharm.D. graduates and five Ph.D. graduates. We continue to monitor the success of our graduates, and while we do not have all of the employment data for 2017 Pharm.D. graduates yet, it is clear that at least 113 of the 123 graduates had decided on positions as either full-time pharmacists or entry into residency programs prior to graduation! Our Ph.D. graduates continue to succeed as well going on to excellent research positions with a variety drug companies and post-doctoral fellowships at other universities. Student success is our number one and primary goal, and while we will miss having all of our graduates around the school, we certainly celebrate their successes and wish them well in their future endeavors. We are also eager to welcome in our new class of students in the fall. Like last year, we will admit up to 95 Pharm.D. students in Kansas City, and up to 30 each in Columbia and Springfield.

    As always, you are all welcome to visit the school anytime at our sites in Kansas City, Columbia, and/or Springfield. We also appreciate your assistance in identifying any students who might be interested in pursuing pharmacy careers. Just let us know, we love to talk to anyone about our great profession! Best wishes to everyone in MSHP!!

    Russell B. Melchert,Ph.D.,R.Ph
    Dean of the School of Pharmacy and Professor, Division of Pharmacology and Toxicology

  • 25 Jul 2017 2:27 PM | Deleted user

    The 2016-2017 academic year has ended at St. Louis College of Pharmacy. On May 12-13, we celebrated our students’ accomplishments at our 149th Commencement, and we welcomed the doctoral class of 2017 into the profession of pharmacy. We also celebrated a milestone with our undergraduate students. For the first time, we awarded Bachelors of Science to students completing their undergraduate studies in the College’s new curriculum implemented in fall 2014.

    The end of the year also provides an opportunity to reflect on all we have accomplished as a community. Nearly three years ago, we began the largest expansion project in the College’s history by breaking ground on the Academic and Research Building (ARB). Today, after adding more than 400,000 square feet of space to campus, we are preparing to open the Recreation and Student Center (RAS).

    The RAS will be a hub of student activity, and the building has been thoughtfully designed to support student life. Students will benefit from one-stop access to study space, academic and personal support resources, dining, and fitness and recreation. The building is the new home to the College’s intercollegiate athletic programs and offers student-athletes a competition gymnasium and training facilities. Faculty and staff are beginning to move into offices and students are beginning to explore the building.

    As these physical changes to our campus unfold, our faculty are taking steps forward through collaborative research.

    The recently established Center for Health Outcomes Research and Education, led by inaugural Director Scott Micek, Pharm.D., associate professor of pharmacy practice, will bring together faculty across campus to focus on six key areas for improvement – nonadherence, delayed evidence-based treatment practice, antibiotic misuse, medication errors, suboptimal generic use and mismanaged polypharmacy. The effort was made possible by a generous contribution from Express Scripts Foundation, which in part, provided funds for the establishment of the center.

    The Center for Clinical Pharmacology, led by Director Evan D. Kharasch, M.D., Ph.D., and Co-Director Karen Seibert, Ph.D., is continuing to make progress toward fulfilling its vision. On May 1, the center welcomed its first two faculty researchers, Ream Al-Hasani, Ph.D., and Jordan G. McCall, Ph.D. Recruitment is underway for three more researchers, who will hold academic appointments at both the College and Washington University School of Medicine in St. Louis.

    This is an exciting time at St. Louis College of Pharmacy! I hope you will visit campus often and see our progress.


    Bruce R. Canaday, Pharm.D., FASHP, FAPhA
    Dean of Pharmacy and Professor

    P.S. The College is hosting the 2017 Reunion Celebration on Saturday, Nov. 11. Join us on campus for a family-friendly reception, Gold Alumni luncheon and a tour of the new buildings. More information is available online at stlcop.edu/reunion.

  • 25 Jul 2017 1:11 PM | Deleted user

    SB 501 was signed by the Governor on July 14 and will become effective on August 28 or other specific dates. Provisions include a statewide protocol for distributing an opioid antagonist; a procedure for prescribing, distributing and administering epinephrine injectors outside of usual prescription requirements; compliance with Medicare Conditions of Participation as the qualifying basis for a hospital license; clarifying a protocol relationship for pharmacists administering vaccines; allowing BOP to expend funds for a drug take-back program for CII and CIII controlled substances; and changes to physician assistant language related to dispensing drugs.

    Click here to read the Senate Bill 501.

  • 25 Jul 2017 12:54 PM | Deleted user
    The PP and PAI Committees have continued to discuss and lead the effort on a possible legislative proposal to modify the scope of practice authorized through medication therapy services protocols with physicians.  A multidisciplinary group was convened in January, has held telephone discussions and met again in July.  The original focus was to revise the language to provide clear prescribing authority and controlled substance authority under MTS protocols.  Additional recommendations included removal of the separate prescription order requirement to implement a protocol, removal of the redundant term medication therapeutic plan and possible inclusion of provider status language.  Considerable discussion has been held between meetings by individual MSHP members at the Spring Meeting and through email communication.  Current reimbursement and provider status laws have been evaluated for both Missouri and other states to determine the best approach to codify pharmacist eligibility.  Since other Missouri professional practice acts do not include a provider status component, and this may dilute the significance of the scope of practice effort, it might be preferable to include provider status in a separate bill under another statute section such as Insurance.  While it is apparent that essentially all current MTS activity is occurring in hospitals and health system clinics, it is also clear that any scope of practice proposal must have the united support of all pharmacy practice settings.  The legislative expertise of both MPA and the Missouri Hospital Association will be sought, as well as lobbying support from individual health systems.  Final bill language will be developed soon and promotional information will be provided for use by groups and individuals when the next session of the General Assembly meets in January.

    The Strategic Planning Committee met on June 24 and included scope of practice legislation and technician legislation proposals as its regulatory priorities for the coming year.  A third priority will be enhancing relationships with the Missouri Hospital Association.

Upcoming events

Copyright 2020, Missouri Society of Health-System Pharmacists
501(c)6 non-profit organization. 2650 S. Hanley Rd., Suite 100, St. Louis, MO 63144 
p: (314) 416-2246, f: (314) 845-1891, www.moshp.org
Powered by Wild Apricot Membership Software